A Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the Literature

Bicky Thapa; Asad Ali; Raunak Nair; Rishik Vashisht; Cassandra Calabrese

doi:10.1155/2019/1326734

A Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the Literature

Case Rep Rheumatol. 2019 Nov 3:2019:1326734. doi: 10.1155/2019/1326734. eCollection 2019.

Authors

Bicky Thapa¹, Asad Ali², Raunak Nair¹, Rishik Vashisht³, Cassandra Calabrese⁴

Affiliations

¹ Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, Ohio, USA.
² Neurological Institute, Taussig Center Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
³ Respiratory Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
⁴ Department of Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Abstract

Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, yet therapy is often hampered by immune-related adverse events (irAEs) which range from mild to severe life-threatening events. Musculoskeletal (MSK) irAEs leading to discontinuation of ICIs are uncommon but increasingly recognized. We report a challenging case of severe immune-related seronegative inflammatory arthritis due to nivolumab in a patient with stage IV metastatic adenocarcinoma.

Publication types

Case Reports